Baker, A., Richmond, R., Haile, M., Lewin, T. J., Carr, V. J., Taylor, R. L., et al. (2006). A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. American Journal of Psychiatry, 163
Bobo, J. K. (1989). Nicotine dependence and alcoholism epidemiology and treatment. Journal of Psychoactive Drugs, 21
Dani, J. A., & Harris, R. A. (2005). Nicotine addiction and comorbidity with alcohol abuse and mental illness. Nature Neuroscience, 8
Diaz, F. J., Rendon, D. M., Velasquez, D. M., Susce, M. T., de Leon, J. (2006). Datapoints: Smoking and smoking cessation among persons with severe mental illnesses. Psychiatric Services, 57
DiFranza, J. R., & Guerrera, M. P. (1990). Alcoholism and smoking. Journal of Studies on Alcohol and Drugs, 51
Gonzales, D., Rennard, S. I., Nides, M., Oncken, C., Azoulay, S., Billing, C. B.
et al. (2006). Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA: The Journal of the American Medical Association, 296
Gunnell, D., Irvine, D., Wise, L., Davies, C., & Martin, R. M. (2009). Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. British Medical Journal, 339:b3805.
Henningfield, J. E., Fant, R. V., Buchhalter, A. R., & Stitzer, M. L. (2005). Pharmacotherapy for nicotine dependence. CA: A Cancer Journal For Clinicians, 55
Hughes, J. R., & Kalman, D. (2006). Do smokers with alcohol problems have more difficulty quitting?
Drug and Alcohol Dependence, 82
Jorenby, D. E., Hays, J. T., Rigotti, N. A., Azoulay, S., Watsky, E. J., Williams, K. E.
et al. (2006). Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA: The Journal of the American Medical Association, 296
Lasser, K., Boyd, J. W., Woolhandler, S., Himmelstein, D. U., McCormick, D., & Bor, D. H. (2000). Smoking and mental illness: A population-based prevalence study. JAMA: The Journal of the American Medical Association, 284
Lawrence, D. M., Holman, C. D., Jablensky, A.V., & Hobbs, M.S. (2003). Death rate from ischaemic heart disease in Western Australian psychiatric patients 1980–1998. British Journal of Psychiatry, 182:31–36.
Marks, J. L., Hill, E. M., Pomerleau, C. S., Mudd, S. A., & Blow, F.C. (1997). Nicotine dependence and withdrawal in alcoholic and nonalcoholic ever-smokers. Journal of Substance Abuse Treatment, 14
Masuhara, J. E., Heath, T., & Okoli, C. (2013). Outcomes of a tobacco treatment programme for individuals with severe and persistent mental illness attending a community mental health team. Journal of Smoking Cessation, doi:10.1017/jsc.2013.17
Oncken, C., Gonzales, D., Nides, M., Rennard, S., Watsky, E., Billing, C. B.
et al. (2006). Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Archives of Internal Medicine, 166
Pomerleau, C. S., Marks, J. L., Pomerleau, O.F. (2000). Who gets what symptom? Effects of psychiatric cofactors and nicotine dependence on patterns of smoking withdrawal symptomatology. Nicotine & Tobacco Research, 2
Tonstad, S., Davies, S., Flammer, M., Russ, C., & Hughe, J. (2010). Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Safety, 33
Vaillant, G. E., Schnurr, P. P., Baron, J. A., & Gerber, P. D. (1991). A prospective study of the effects of cigarette smoking and alcohol abuse on mortality. Journal of General Internal Medicine, 6
Xian, H., Scherrer, J. F., Madden, P. A., Lyons, M. J., Tsuang, M., True, W. R.
et al. (2005). Latent class typology of nicotine withdrawal: genetic contributions and association with failed smoking cessation and psychiatric disorders. Psychological Medicine, 35